Immunocore
IMCR
130 hedge funds and large institutions have $1.41B invested in Immunocore in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 49 increasing their positions, 38 reducing their positions, and 26 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 38
2.2% more ownership
Funds ownership: 88.36% → 90.56% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $1.46B → $1.41B (-$51.4M)
6% less funds holding
Funds holding: 138 → 130 (-8)
31% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 26
56% less call options, than puts
Call options by funds: $6.62M | Put options by funds: $15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$128M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$25.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.3M |
| 4 |
Primecap Management
Pasadena,
California
|
+$18.9M |
| 5 |
Two Sigma Advisers
New York
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$27M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24.5M |
| 3 |
Morgan Stanley
New York
|
-$16.9M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$14.2M |
| 5 |
Renaissance Technologies
New York
|
-$13.5M |
IMCR Hedge Fund Activity: Q3 2024 in Review
130 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q3 2024, worth a combined $1.41B — down 3.5% from $1.46B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of IMCR and 18 opened new positions — a net loss of 8 holders — while 38 trimmed existing stakes and 49 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $128M. The largest seller was Braidwell, exiting entirely with an estimated $27M sold.
- 130 institutional investors held Immunocore (IMCR) as of Q3 2024, down from 138 in Q2 2024.
- Funds reported $1.41B of Immunocore stock for Q3 2024, down 3.5% quarter-over-quarter.
- 18 funds opened new Immunocore positions in Q3 2024 and 26 closed out, a net change of -8 holders.
- The largest Immunocore buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $128M added.
- The largest Immunocore seller in Q3 2024 was Braidwell, an estimated $27M sold.
Based on aggregated 13F filings for Q3 2024.